



AGRAFLOA ORGANICS INTERNATIONAL INC.

Management's Discussion and Analysis

For the Years Ended December 31, 2020 and 2019

(Expressed in Canadian Dollars)

AGRAFLOA ORGANICS INTERNATIONAL INC.
Management's Discussion and Analysis
(Expressed in Canadian Dollars)

Date: May 3, 2021

INTRODUCTION

This Management's Discussion and Analysis ("MD&A") of the operating results and financial condition of AgraFlora Organics International Inc. ("AGRA" or the "Company") for the year ended December 31, 2020 should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2020, which are prepared in accordance with International Financial Reporting Standards ("IFRS").

Management is responsible for the preparation and integrity of the financial statements, including the maintenance of appropriate information systems, procedures, and internal controls and to ensure that information used internally or disclosed externally, including the financial statements and MD&A, are complete and reliable. The Company's board of directors (the "Board") follows recommended corporate governance guidelines for public companies to ensure transparency and accountability to shareholders. The Board's Audit Committee meets with management quarterly to review the financial statements, the MD&A and to discuss other financial, operating, and internal control matters. The reader is encouraged to review the Company's statutory filing on www.sedar.com.

This MD&A is prepared as at May 3, 2021. All dollar figures stated herein are expressed in Canadian dollars unless otherwise indicated.

Readers should use the information contained in this report in conjunction with all other disclosure documents including those filed on SEDAR at www.sedar.com.

Forward-Looking Statements

Information set forth in this MD&A may involve forward-looking statements within the meaning of Canadian securities laws. These statements relate to future events or future performance and reflect management's expectations regarding the Company's growth, results of operations, performance and business prospects and opportunities. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. In some cases, forward-looking statements can be identified by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue", "target" or the negative of these terms or other comparable terminology. Forward-looking statements in this MD&A include, but are not limited to: volatility of stock price and market conditions, regulatory risks, difficulty in forecasting, key personnel, limited operating history, competition, investment capital and market share, market uncertainty, additional capital requirements, management of growth, pricing policies, litigation, no dividend history. The risk factors described in this MD&A are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in the Company's forward-looking statements. In addition, any forward-looking statements represent the Company's estimates only as of the date of this MD&A and should not be relied upon as representing the Company's estimates as of any subsequent date. The material factors and assumptions that were applied in making the forward-looking statements in MD&A include:

- the Company's use of proceeds and business objectives and milestones and the anticipated time of execution, see "Use of Proceeds";
- the performance of the Company's business and operations;
- the intention to expand the business, operations and potential activities of the Company;
- the methods used by the Company to deliver cannabis;
- the projected increase in production capacity;
- the competitive conditions of the cannabis industry;
- the competitive and business strategies of the Company;

INTRODUCTION (CONTINUED)

Forward-Looking Statements (continued)

- the Company's anticipated operating cash requirements and future financing needs;
- the anticipated future gross revenues and profit margins of the Company's operations;
- the Company's expectations regarding its revenue, expenses and operations;
- impacts of potential litigation;
- the Company's intention to build brands and develop cannabis products targeted to specific segments of the market;
- the ongoing and proposed expansion of the Company's facilities, products or services, including associated costs and any applicable Health Canada licensing;
- the current political, legal and regulatory landscape surrounding medical and recreational cannabis and expected developments in any jurisdiction in which the Company operates or may operate;
- the receipt of any regulatory and stock exchange approvals required at any given time;
- the applicable laws, regulations and any amendments thereof;
- medical benefits, viability, safety, efficacy and dosing of cannabis;
- the expected growth in the number of patients;
- the expected number of grams of medical cannabis used by each patient;
- expectations with respect to the advancement and adoption of new product lines and ingredients;
- the acceptance by customers and the marketplace of new products and solutions;
- the ability to attract new customers and develop and maintain existing customers;
- expectations with respect to future production costs and capacity;
- expectations with respect to the renewal and/or extension of the Company's permits and licenses;
- the ability to protect, maintain and enforce the Company's intellectual property rights;
- the ability to successfully leverage current and future strategic partnerships and alliances;
- the ability to attract and retain personnel;
- anticipated labour and materials costs;
- the Company's competitive condition and expectations regarding competition, including pricing and demand expectations and the regulatory environment in which the Company operates; and
- anticipated trends and challenges in the Company's business and the markets and jurisdictions in which the Company operates or may operate.

The preceding list is not exhaustive of all possible factors. All factors should be considered carefully when making decisions with respect to the Company. Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. Unless required by applicable securities laws the Issuer disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. For a description of material factors that could cause the Company's actual results to differ materially from the forward-looking statements in this MD&A, see "Risk Factors".

While the Company considers these assumptions may be reasonable based on information currently available to it, these assumptions may prove to be incorrect. Actual results may vary from such forward-looking information for a variety of reasons, including but not limited to risks and uncertainties disclosed in the section titled "Risk Factors".

AGRAFLORA ORGANICS INTERNATIONAL INC.
Management's Discussion and Analysis
(Expressed in Canadian Dollars)

OVERVIEW

The Company was incorporated on June 24, 2004 under the laws of the Province of British Columbia.

The Company trades on the Canadian Stock Exchange (the "CSE") under the symbol "AGRA". The Company also trades on the OTC Pink Sheets ("OTCPK") under the symbol "AGFAF" and the Frankfurt Stock Exchange under the symbol "PU3".

The Company is a vertically integrated cannabis company equipped with a robust portfolio of licensed upstream, downstream and product formulation assets. The Company owns and operates an ACMPR licensed indoor cultivation operation in London, ON, and controls a 70% interest in Propagation Service Canada and its large-scale, 2.2 million square foot greenhouse complex in Delta, B.C. The Company's Delta Greenhouse Complex is equipped with 2.2 million square feet of dedicated cultivation area under glass and is widely considered to be one of the most technically advanced and environmentally efficient greenhouse operations in the world.

OVERALL PERFORMANCE

During the year ended December 31, 2020, the Company completed two key acquisitions in Sanna and Farmako, and continued to develop on its Delta Greenhouse and Edibles Facility. Subsequent to the year-ended December 31, 2020, Agraflorea Organics International Inc. and its fellow shareholders have entered into an agreement to sell The Edibles & Infusions Corp., an entity of which Agraflorea owns 43 per cent, to Organigram Holdings Inc. for consideration of \$22-million in shares of Organigram plus up to an additional \$13-million in shares of Organigram receivable upon the EIC business achieving certain earn-out milestones. The EIC transaction strongly positions Agraflorea for the future with its net share of up to \$35-million in aggregate proceeds as it continues to evolve its competitive strategy within the changing global cannabis industry.

Propagation Services Canada

As at December 31, 2020 and the date of this MD&A, the Company controls 70% of PSC's flagship Delta Greenhouse Complex (the "Delta Facility"). The Company's investment in the Delta Greenhouse is widely considered to be one of the most technically advanced and environmentally-friendly greenhouse operations in the World, which boasts industry leading cultivation infrastructure including:

- Fully integrated on-site natural gas-powered power plant;
 - Providing ample heat and electricity, while repurposing carbon dioxide emissions to benefit the plants.
- Proprietary energy efficient air exchange to maintain stable climate conditions;
- Advanced climate and humidity control management infrastructure;
- Ebb and flow watering systems to enhance complete irrigation recapture and water treatment; 1.5-million-gallon hot water storage tank configured to store energy produced during the day, for redistribution during non-peak hours, thereby increasing operational efficiencies and reducing associated energy costs;
- Multistage supplemental lighting augmented by natural sunlight to foster an optimized illumination equilibrium; and,
- Proprietary ERP system to allow for efficient resource management and cost tracking.

On February 28, 2020, PSC entered into an agreement to acquire a portfolio of elite live-plant cannabis genetics (the "Live-Plant Genetics") from an award-winning Canadian cannabis cultivator with extensive experience in genetic development and commercialization for at-scale cannabis production. The acquisition of Live-Plant Genetics will accelerate PSC's go to market strategy and utilized along with the Company's Standard Cultivation License.

OVERALL PERFORMANCE (CONTINUED)

Propagation Services Canada (Continued)

On May 19, 2020, PSC secured a Standard Cultivation License from Health Canada and has commenced cultivation of a curated portfolio of elite live plant genetics. The Delta Facility's first phase represents 422,828 square feet of cultivation space.

During the period, PSC has commenced cultivation using a curated portfolio of live-plant genetics (the "Elite Genetics") with a focus on producing high potency cannabis with attractive strains, while maintaining a low cost. Management anticipates the combination of high potency and low cost will result in a product that is attractive to consumers in the retail and wholesale markets. The Delta facility expects to move to first harvest by early fourth quarter with first product available for sale of low-cost high-potency cannabis strains expected in Q1 2021 on a wholesale basis.

The Elite Genetics at the Delta Facility have been tailored to go to work with PSC's infrastructure and cultivation program and are expected to yield up to 44 varieties of strains to offer the Company's wholesale clients a robust product offering while maintaining strong cannabinoid and terpene content plant yield and crops per year.

On November 23, 2020, the Company announced that the Delta Facility has received an Agriculture Loan (the "Loan") to bring its cannabis cultivation to market and continue Phase 1 of the Company's cultivation strategy. As part of the Loan, the Delta Facility will receive \$5,000,000 which will provide full funding to the licensed cultivation areas and will allow the PSC team to bring their first crop of low cost, high potency cannabis to market, on a wholesale basis, in Q1 2021. The curated portfolio of elite genetics at the Delta facility has been tailored to work with PSC's Delta based infrastructure and utilizing 422,828 sq. ft. of cultivation space with state-of-the-art semi pressurized, semi-open Venlo greenhouses.

On December 10, 2020, the Company provided 2021 guidance highlights. PSC will expect to cultivate 10,000 plants and aims to yield 50 grams per plant of saleable product, first sales expected in Q2 of 2021.

The Edibles and Infusions Joint Venture

By way of an executed Asset Purchase Agreement (the "Agreement") with Organic Flower Investments Group Inc. ("Organic Flower"), the Company controls an 80% interest in The Edibles and Infusions Corp. ("Edibles and Infusions"), a joint venture ("JV") with one of North America's largest and most storied manufacturer and distributor of chocolate and sugar confectionary products. Upon successful receipt of appropriate Health Canada Licensing, the JV will produce an assort of both cannabinoid/terpene-infused products for medicinal, functional and adult use. Edibles and Infusions operates a 51,500 square foot edibles manufacturing facility located in Winnipeg, Manitoba ith over 30,000 square feet of dedicated edibles production space.

The Company's JV partner was established nearly a century ago and has since become North America's largest confectionary fruit slice manufacturer, supplying products to over 20,000 locations across North America, most prominently Costco and Wal-Mart.

Equipped with a roster of experienced chocolatiers and confectioners, as well as established industry relationships and best-in-class supply chain management infrastructure, the Company's JV partner currently manufactures and distributes several hundred unique stock keeping units ("SKUs").

The Company was awarded a 5-year cannabis research license from Health Canada under the Cannabis Regulations Act for the Winnipeg Edibles Facility. Upon receipt of appropriate Health Canada licensing, the Company will supply the JV with inputs for the edibles manufacturing process such as artisanal, ultra-premium dried cannabis flower, as well as premium cannabis trim from its Delta Greenhouse Complex and ACMPR licensed AAA Heidelberg facility.

OVERALL PERFORMANCE (CONTINUED)

The Edibles and Infusions Joint Venture (continued)

Receipt of full-spectrum cannabinoid concentrates is expected post licensing to assist with product development and ancillary research and development activities. The Company has completed construction of its 750 square foot, pharmaceutical-grade research and development laboratory (the "R&D Laboratory") at the Winnipeg Edibles Facility.

The Company's R&D Laboratory boasts a comprehensive suite of made-to-order cannabinoid-testing and product formulation equipment, including:

- High Performance Liquid Chromatography ("HPLC");
- Microbiological testing instruments;
- Custom confectionery testing, manufacturing and origination/formulation technologies;
- Deposit throughput in excess of 1000 pieces of premium chocolates or gummy edibles per hour;
- Proprietary triple shot depositor capable of producing infused chocolate or liquid filled center in shell pieces, as well as a full vacuum pressure confectionery-cooking system.

The Company's Winnipeg Edibles Facility is a state-of-the-art commercial scale edibles facility that features industry leading manufacturing equipment and automation for the production of cannabis edibles. The Company intends to focus initially on the production of THC and CBD infused cannabis gummies. The Winnipeg Edibles Facility is operated by a roster of third generation chocolatiers/confectioners and boasts state-of-the-art manufacturing equipment capable of producing an assortment of both cannabinoid/terpene-infused products for medicinal, functional and adult use.

Development of the Edibles facility was completed on June 3, 2020. On May 28, 2020, Edibles and Infusions submitted its Site Evidence Package for its Standard Processing and Cultivation License to Health Canada.

The Company has received a necessary CRA tax license and is now creating test cannabis edibles products through its Health Canada licensed Research and Development Lab ("R&D Lab") within its Facility.

On October 2, 2020, the Company submitted a formal response to Health Canada's first Request for More Information ("RMI") regarding the Standard Processing License (the "Manufacturing License") application for the Company's Winnipeg Edibles Facility. The RMI response is a key step towards achieving the Standard Processing License at the Edibles Facility. The Company announced receipt of the Manufacturing license on December 11, 2020.

On January 13, 2021, the Company completed the first phase of its R&D trials at its Winnipeg Edibles Facility and expects to enter the edibles market in Q1 of 2021.

On February 8, 2021, the Company issued 150,580,723 common shares pursuant to the third amending agreement (the "Third Amending Agreement") with Mulberry Capital Corp. ("Mulberry") related to the Share Purchase Agreement in the prior year. Pursuant to the Third Amending Agreement, the Company is obligated to pay the remaining unpaid portion of the purchase price of the Joint Venture Agreement between SUHM and Quality Confections Canada Ltd. of an aggregate maximum of \$27,500,000 which shall be forgone by Mulberry in consideration for the following:

- the Company reconveying a 26.5% ownership interest in SUHM which is non-dilutable to Mulberry until the Company has advanced \$7,000,00 to fund Edibles' facility in Winnipeg by way of equity or debt; and
- the Company issuing 10% of the issued and outstanding shares of the company to Mulberry on the date that is the later of it issuing shares pursuant to the Joint Venture Agreement and the date it has satisfied its interest payment in common shares to holders of convertible debentures.

Following the completion of the Offering and payment of the consideration under the Amending Agreement, the Company would own approximately 49.75% of the joint venture comprising the Winnipeg facilities.

OVERALL PERFORMANCE (CONTINUED)

The Edibles and Infusions Joint Venture (continued)

On March 10, 2021, the Company acquired equipment for its Winnipeg Edibles Facility through the issuance of 10,000,000 common shares with a fair value of \$300,000.

On April 6, 2021, the Company and the other owners of Edibles have entered into an agreement to sell Edibles to Organigram Holdings Inc. ("OGI") for consideration of \$22 million in shares of OGI (the "Edibles Transaction"), plus up to \$13 million in shares of OGI (the "Additional Consideration") receivable upon Edibles achieving certain earn-out milestones.

The gross purchase price receivable by the Company and the other shareholders on closing of the Edibles Transaction is \$22 million, receivable in full by the issuance of 5,045,872 common shares of OGI based on its closing price of \$4.36 on April 5, 2021. Upon satisfaction of the Milestones, OGI will issue up to an aggregate of an additional \$13 million of its common shares proportionately to the Company and the other shareholders, for which the number of common shares will be determined upon achievement of each Milestone. The Milestones include:

- \$3.5 million to be received in common shares of OGI on first listing prior to December 31, 2021 in either the Ontario or Alberta recreational market of Edibles or Organigram branded product (which was manufactured at the Edibles facility);
- \$7.0 million to be received in common shares of OGI on the successful completion of \$15 million in net revenue during the 12 months ended December 31, 2022;
- \$2.5 million to be received in common shares of OGI on the generation of \$7 million in Adjusted EBITDA for the 12 months ended December 31, 2022.

Canutra Naturals Ltd.

Pursuant to the terms of an executed asset purchase and sale agreement between Organic Flower and the Company, the Company now owns 100% of Canutra Naturals Ltd. ("Canutra"). Canutra manufactures and distributes premium personal care, cosmetics and cannabinoid-infused product lines including a suite of trusted consumer brands such as Whole Hemp Health; a Canadian all-natural, hand-made skin care line, formulated with 100-per-cent-Canadian organic hemp seed oil. Canutra markets its Whole Hemp Health products by way of brick-and-mortar retail outlets, Amazon Prime, as well as direct to consumer, through an integrated Shopify e-commerce platform.

Canutra owns and operates 76 acres of unzoned, arid agricultural land, including 1,000 feet of river frontage in New Brunswick. The New Brunswick campus, formerly a federally owned farm and research facility, boasts over 17,500 square feet of commercial-grade production facilities, as well as 12 separate free-standing structures. This acquisition equips the Company with robust cultivation, extraction, manufacturing and distribution capabilities from the company's New Brunswick facility.

In September 2019, Canutra has been awarded a cannabis research license (the "Research License") by Health Canada under the Cannabis Regulations Act. The Research License permits Canutra to pursue the development of proprietary cannabis genetics and phenotypes.

OVERALL PERFORMANCE (CONTINUED)

Canutra Naturals Ltd. (Continued)

Canutra continues to demonstrate its leadership with regards to cannabis-derived CPGs, due to its Health Canada awarded Research License and continued collaboration with UM. The company also continues to achieve material advancements throughout its IP development and aggregation initiatives, including:

- High CBD hemp cultivation techniques;
- Advanced extraction methodologies;
- Cultivar development;
- Inoculation formulations; and
- Proprietary cannabinoid profiles for future skin care product lines.

The Company received a purchase order from Tobmar Newstands ("TN") for its Whole Hemp Health organic lip balm SKU. TN's purchase order and subsequent listing of a secondary SKU secures additional high visibility Canadian shelf space for the Company's expanding line of organic cannabis sativa seed oil infused consumer packaged goods ("CPGs").

During the year ended December 31, 2020, Canutra sold its land with a cost of \$373,700 for total proceeds of \$682,372 and record a gain on sale of \$308,672. The Company entered into a promissory note of \$275,000 with the purchaser relating to the sale.

AAA- Heidelberg Inc.

AAA Heidelberg is a licensed cannabis cultivation facility under Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The AAA Heidelberg facility is equipped with five partitioned flower rooms, affording the Company ample canopy earmarked for ultra-premium craft cannabis cultivation. The Company is presently working to import a catalogue of premium craft cannabis genetics into its AAA Heidelberg facility, under a one-time declaration from Health Canada. Upon completion of a test harvest, as well as the associated test crop submissions and approvals from Health Canada, the Company plans to apply for both sales and processing licences at its AAA Heidelberg craft cannabis facility; with the objective of producing finished cannabis form factors for domestic distribution including, soft gels, tinctures, distillates and THC oils.

On April 1, 2021, the Company signed a definitive agreement to sell its wholly-owned subsidiary, AAA Heidelberg Inc. for cash consideration of approximately \$1,000,000.

Sanna Health Corp.

On March 10, 2020, the Company closed the acquisition of 100% of the issued and outstanding common shares of Sanna Health Corp. ("Sanna") pursuant to a Share Purchase agreement dated March 10, 2020. As consideration, on March 10, 2020, the Company issued 76,666,666 common shares of the Company with a fair value of \$6,168,221.

Sanna is a Canadian cannabis company based in the Toronto Canada and boasts the following licenses awarded under the Access to Cannabis for Medical Purposes Regulations ("ACMPR"):

- Standard Cultivation License;
- Standard Processing License; and,
- Medical Sales License.

The acquisition of Sanna is a transformative acquisition that will provide four strategic advantages:

1. Double forecasted 2020 production capacity;
2. Sanna's existing on-site infrastructure will allow for complementary, margin rich extraction capabilities;
3. Access to proven and popular, market-leading brand/product portfolio; and,
4. Enhance high-visibility distribution across Canada.

OVERALL PERFORMANCE (CONTINUED)

Sanna Health Corp. (Continued)

Sanna's flagship facility is situated on 16 acres and includes 27,000 square feet of Health Canada licensed cultivation and processing space with an option to expand current production to 89,000 square feet. Sanna has finalized distillate supply contracts and has ethanol extraction equipment on-site which will help realize sustainable near term cash flows. It is forecasted that Sanna's extraction facility will boast annual extraction capacity of 250,000 kilograms of dried cannabis and hemp biomass.

Sanna holds exclusive Canadian license for the award winning MUV portfolio of premium cannabis products developed and distributed by Florida-based Altmed Enterprises, LLC ("Altmed"). Altmed is a state-leading pharmaceutical grade medical cannabis company.

Sanna has entered into a cultivation partnership (the "Cultivation Partnership" or the "Agreement") for hemp cultivation in Ontario. Pursuant to the Cultivation Partnership, SGCS has successfully planted fifty (50) acres of high-quality hemp at a farm in Brinbrook Ontario (the "Binbrook Farm"). The Company anticipates the Binbrook Farm will yield approximately 50,000 kilograms of high CBD hemp in fall 2020.

The Good Company GmbH

The Company acquired 100% of the issued and outstanding shares of The Good Company GmbH ("The Good Company"). The Good Company is the parent company of German European Union good distribution practice medical cannabis distributor (EU-GDP) Farmako GmbH ("Farmako"). Farmako is a leading European medical cannabis distributor, headquartered in Frankfurt, Germany, with affiliated companies in the United Kingdom, Luxembourg and Denmark.

This acquisition expedited the Company's entrance into the European cannabis theatre by arming the Company with existing cannabis distribution infrastructure, supply and licenses/certifications, all while equipping the Company with experienced European cannabis operators. The combined AgraFlora-Farmako entity will function as a high-margin European distribution hub for the Company's medical cannabis flower and EU-GMP certified manufactured cannabis products produced from its Delta Greenhouse Facility, AAA Heidelberg craft cannabis facility and 27,000 square foot Scarborough, Ontario cultivation and processing facility.

On February 18, 2020, Farmako secured a special authorization from the German Federal Institute for Drugs and Medical Device for the distribution of medical cannabis flowers that have undergone an ionizing radiation treatment.

This is a critical milestone for Farmako, as Farmako can now import for sale in Germany medical cannabis that is EU-GMP certified.

On September 15, 2020, Farmako secured an additional supply of EU-GMP Cannabis by execution of the binding supply agreement with ZenPharm Ltd., a subsidiary of Zenabis Global Inc. (TSX: ZENA). Pursuant to the Supply Agreement, ZenPharm will supply EU-GMP quality medical cannabis flower cultivated by Zenabis to Farmako for distribution to medical cannabis patients in Germany. The agreement is intended to facilitate the distribution of 1,500 kilograms of cannabis flower by Farmako in Germany over a 3 year term. Farmako will distribute the products to its established network of German pharmacies. The products will carry Farmako's branding, an important step in building brand awareness and loyalty with physicians, pharmacists and patients. The products initially include high potency THC flower and balanced THC and CBD flower, two product categories that management believes are in highest demand in Germany.

OVERALL PERFORMANCE (CONTINUED)

The Good Company GmbH (Continued)

On April 12, 2021, Farmako announced that it has begun supplying STADAPHARM GmbH ("STADAPHARM") with its proprietary THC Testkits (the "THC Testkits"). The THC Testkits were developed and produced by Farmako in-house and will be supplied to STADAPHARM as a tool for pharmacists to detect THC and identify medical cannabis flowers and extracts in an easy, quick and cost-efficient way. STADAPHARM, which is responsible for the Specialty Pharmaceuticals business within the STADA Group, will be entering the medical cannabis market in the second quarter of 2021. The company will launch its own THC-containing cannabis flower products and extracts and will also offer the THC Testkits, developed and produced by Farmako, along with its own products to pharmacists for the identity testing of medical cannabis.

Health Canada Licensing

The Company and its associated principal subsidiaries have the following licenses:

- Standard cultivation and processing license at the Delta Greenhouse Facility;
- Industrial hemp license at its 2.2 million square foot Delta Greenhouse Facility;
- Standard cultivation license at its Sustainable Growth Strategic Facility (Sanna);
- Standard processing license at its Sustainable Growth Strategic Facility (Sanna); and,
- Medical sales license at its Sustainable Growth Strategic Facility (Sanna); and,
- Standard cultivation license at its Canutra Facility; and,
- Cannabis research license at its Canutra Facility.

OUTLOOK

Agraflo's operating portfolio affords the company unmatched Cannabis 2.0 optionality as the industry continues to mature. As Propagation Services Canada continues its momentum toward its first commercial sales and is expected to report initial revenue summer, 2021. The first commercial crop for commercial sale will include three proprietary strains: Mimosa 37, Kosher Kush and Gelato. These strains have been selected for their strong demand in Canada's dried flower market, as well as their growing attributes within the greenhouse environment which align with their low-cost high-THC cannabis attributes. PSC has gathered valuable data from crops grown to date and continues to develop and strategize to further aid in its positioning as a leader in low-cost product.

PSC will be optimizing its propagation operations by fine-tuning its climate strategy to produce healthy, rooted cuttings more quickly with high-success-rate monitoring irrigation mixtures to produce custom nutrient formulations for each stage of plant growth. By developing novel production strategies, PSC can maximize yield per square metre with minimal labour costs leveraging best growing practices and experience in vegetable cultivations and applying to them to its cannabis operation.

EQUITY TRANSACTIONS

On January 6, 2020, the Company issued 800,000 common shares with a fair value of \$68,000 pursuant to a supply agreement entered into with Vendure Genetics Labs Inc. dated December 26, 2018 and amended on December 16, 2019 for the supply of certain cannabis plants and intellectual property rights.

On January 17, 2020, the Company issued 58,823,529 common shares with a fair value of \$5,882,353 in relation to investment in SUHM.

On January 28, 2020, the Company issued 6,666,667 common shares with a fair value of \$616,667 of the Company upon conversion of the Special Warrants issued on September 19, 2019.

AGRAFLORA ORGANICS INTERNATIONAL INC.
Management's Discussion and Analysis
(Expressed in Canadian Dollars)

EQUITY TRANSACTIONS (CONTINUED)

On March 10, 2020, the Company acquired 100% of Sanna Health Corp pursuant to a Share Purchase Agreement dated March 10, 2020. As consideration, the Company issued 76,666,666 common shares of the Company with a fair value of \$6,168,221.

On April 7, 2020, the Company issued 3,731,846 common shares with a fair value of \$186,592 to settle debt of \$362,508 and recorded a gain on debt settlement of \$175,916.

On April 30, 2020, the Company closed a non-brokered private placement offering of 266,666,667 units of the Company at a price of \$0.075 per Unit for gross proceeds of \$20,000,000. Each Unit consists of one common share and one transferable share purchase warrant. Each warrant is exercisable to purchase one common share of the Company for a period of five years at a price of \$0.10 per share. The \$20,000,000 tranche, consisted of the settlement of a convertible debenture and debt owed to arm's length parties of \$17,666,208 and \$2,334,000 respectively. The fair value of the shares issued was \$14,666,667 and a value of \$6,788,307 was assigned to the warrants.

On May 4, 2020, the Company issued 2,692,905 common shares with a fair value of \$148,110 to settle debt of \$201,968 with certain creditors for past consulting and other services provided to the Company and recorded a gain on debt settlement of \$53,858.

On May 25, 2020, the Company closed the second tranche of its non-brokered private placement offering of 20,700,000 Units of the Company at a price of \$0.075 per Unit for gross proceeds of \$1,552,500. Each Unit consists of one common share and one transferable share purchase warrant. Each warrant is exercisable to purchase one common share of the Company for a period of five years at a price of \$0.10 per share. The fair value of the shares issued was \$1,449,000 and a value of \$103,500 was assigned to the warrants. In connection with the private placement, the Company paid a cash finder's fee of \$3,150 and 42,000 Finder's Warrants. The Finder's Warrants have the same terms as the Unit warrants with a fair value of \$2,589.

On June 5, 2020, the Company issued 22,802,938 common shares with a fair value of \$1,500,000 for transaction cost pursuant to the Edibles acquisition.

On July 8, 2020, the Company completed a non-brokered private placement of 11,612,000 units of the Company at a price of \$0.075 per Unit for gross proceeds of \$870,900. Each Unit consists of one common share and one transferable common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional common share for a period of five years from closing at a price of \$0.10 per common share. The fair value of the shares issued was \$580,600 and a value of \$290,300 was assigned to the warrants.

On August 7, 2020, the Company issued 82,233,999 common shares with a fair value of \$4,317,285 pursuant to the Exchange Agreements with holders of the Company's 10% convertible debentures providing for the purchase of \$3,000,000 aggregate principal amount of the debentures (the "Purchased Securities"). In exchange for the Purchased Securities, the Company issued 54,822,666 common shares at a price of \$0.05472 per share. Further, the Company issued 27,411,333 common shares to satisfy the aggregate interest payment of \$1,500,000 (the "Accrued Interest") owing on June 30, 2020 on a pro-rata basis to the holders of the Debentures. The Company recorded a gain on debt settlement of \$182,715.

On August 7, 2020, the Company issued 4,000,000 common shares with a fair value of \$210,000 to settle debt of \$220,000 for services rendered and recorded a gain on debt settlement of \$10,000.

On August 20, 2020, the Company returned 542,426 common shares to treasury which were previously issued on May 4, 2020 to a creditor for past consulting and other services valued at \$68,440 and recorded a reversal of gain on debt settlement of \$18,250. The Company and the creditor have agreed to an alternative to settle the debt at a future date.

On December 11, 2020, the company closed a share for debt transaction with a certain creditor for \$792,303 for past services rendered to the Company. A total of 15,000,000 common shares were issued to the creditor with a fair value of \$450,000 for full satisfaction of the debt owed by the Company.

AGRAFLORA ORGANICS INTERNATIONAL INC.
Management's Discussion and Analysis
(Expressed in Canadian Dollars)

SELECTED ANNUAL INFORMATION

A summary of selected annual financial information for the last three fiscal years as follows, as expressed in Canadian dollars:

	As at December 31, 2020 (\$)	As at December 31, 2019 (\$)	As at December 31, 2018 (\$)
Total revenues	1,491,678	3,888	Nil
Net loss	103,203,264	101,691,169	5,820,218
Comprehensive loss	103,195,077	101,691,169	5,820,218
Net loss per share	(0.08)	(0.18)	(0.02)
Total assets	61,732,883	107,616,699	29,994,593
Total liabilities	58,004,320	41,517,146	324,632

During the year ended December 31, 2020, the Company impaired its convertible loan receivable, totaling \$29,210,673, tangible and intangible assets of \$16,532,620, impaired investments of \$8,459,812 and wrote-off accounts receivable of \$1,158,462, which contributed to the overall decrease in total assets relative to the assets held at December 31, 2020. These decreases were offset with the acquisition of Sanna Health and Farmako. The amount and timing of expenses and availability of capital resources vary substantially from year over year, depending on the availability of funding from investors or collaboration partners. During the year ended December 31, 2020, total revenues increased to \$1,491,678 from \$3,888, due to the acquisition of Farmako.

SUMMARY OF QUARTERLY RESULTS

Quarter Ended	Total Assets (\$)	Revenue (\$)	Comprehensive Loss for the period (\$)	Loss per Share (Basic & Diluted) (\$)
March 31, 2019	51,015,985	-	(6,656,302)	(0.02)
June 30, 2019	60,277,480	-	(12,323,239)	(0.03)
September 30, 2019	162,666,863	-	(38,002,761)	(0.05)
December 31, 2019	107,616,669	3,888	(44,708,868)	(0.08)
March 31, 2020	137,144,917	365,035	(9,689,125)	(0.01)
June 30, 2020	140,005,787	457,344	(7,087,545)	(0.01)
September 30, 2020	138,813,735	420,732	(5,091,944)	(0.00)
December 31, 2020	61,732,883	248,567	(81,326,463)	(0.06)

Fluctuation in assets are mostly due to cash from financing activities and the acquisition of certain businesses and assets during a specific quarter. The amount and timing of expenses and availability of capital resources vary substantially from quarter to quarter, depending on the availability of funding from investors or collaboration partners. Total revenues decreased in Q4 2020 relative from the comparative quarters due to certain adjustments effecting revenues.

Expenses during Q4 2020 grew significantly as the Company completed its impairment review for a significant number of assets and wrote off tangible and intangible assets of \$16,532,620, accounts receivable of \$1,158,462 and the Company's convertible loan receivable of \$29,210,673. Such adjustments were not recorded in previous quarters. In addition, the Company finalized its purchase price allocation for its business combination with Farmako, which led to an overall change in the net assets acquired.

RESULTS OF OPERATIONS

The Company's loss for the year ended December 31, 2020 was \$103,203,264 compared to a loss of \$101,691,169 for the year ended December 31, 2019. In general, for the comparative period, the Company had less activity than the current period but the Company incurred higher expenditures primarily attributable to costs related to acquisitions and share-based payments. The previous period is therefore not indicative of the current period and therefore does not provide the reader with an appropriate benchmark to evaluate performance year over year. Explanations of the nature of costs incurred, along with explanations for those changes in costs are discussed below for the year ended December 31, 2020.

- Professional fees increased to \$2,100,637 from \$715,737. During the year ended December 31, 2020, the Company acquired two wholly owned subsidiaries resulting in increased professionals during the due diligence phase. The Company incurred legal, accounting, and other professional fees associated with the acquisitions.
- Consulting and management fees decreased to \$7,677,008 from \$13,188,159 as in the previous year, the Company hired consultants and various fees in connection with the acquisitions in 2019 and 2020. The decrease reflects the completion of the acquisitions in the current year. The Company relies heavily on Consultants to achieve its goals on all facets of business and these industry consultants bring a wide range of expertise and connections to the Company. Consultants include Management, Product Development Advisors, Technical Support and other support roles. The Company continues to receive unrivalled support from its best-in-class joint-venture partners and industry consultants. The Company owns two state of the art Cannabis production facilities in Canada and a significant portion of the expenditures relates to consulting fees paid to various vendors on the development of the project as well as negotiations for the other downstream assets purchased during the period.
- Amortization increased to \$1,019,300 from \$151,477 as the Company added new property, plant and equipment in second half of 2019 and 2020. The Company incurred the vast majority of amortization due to accounting treatment under IFRS 16 – leases, and the Company amortized its two right-of-use lease assets. The remainder of amortization expense is from amortization of property plant and equipment and intangible assets.
- Investor communications fees decreased to \$23,184 from \$288,379 as the Company focused more efforts to raise investor awareness in the prior year during its various acquisitions.
- Development and compliance expense increased to \$159,007 from \$56,205. Development and compliance expenses incurred relate to the Company's costs to ensure it is compliant with the various jurisdictions of its operations.
- Corporate development expense decreased to \$976,193 from \$4,075,429. Corporate development consists of expenses incurred to increase the Company's global brand awareness and presence in the Cannabis industry in multiple countries. Q2 2019 was a crucial quarter for the Company, with the Company completing numerous acquisitions during and subsequent to the period. During the year ended December 31, 2020, the Company has reduced its corporate development expense as a cost-cutting measure.
- Office and sundry expenses increased to \$454,426 from \$269,412 which is a result of the expansion of the Company compared to the prior year.
- Wages and salary increased to \$1,292,195 from \$39,660 as the Company hired employees in the second half of 2019 and during the year ended December 31, 2020.
- Regulatory and transfer agent fees decreased to \$232,216 from \$513,751 as a result of the Company's preparations in the prior period to complete regulatory filings for its acquisitions.
- Rent expense increased to \$96,240 from \$46,858 as a result of the Company's acquisitions of certain subsidiaries where rent expenses are incurred for property taxes and insurance on their commercial leases.
- Share based compensation decreased to \$3,396,618 from \$37,133,311 as the Company less granted stock options to directors, officers and consultants and completed various acquisitions through share-based transactions during the year ended December 31, 2020. The Company uses share-based compensation as an alternative to incentivize the management term to return shareholder wealth and as an alternative form of payment to preserve cash.

RESULTS OF OPERATIONS (CONTINUED)

- Transaction costs decreased to \$5,878,353 from \$30,110,126 and consists of non-cash transaction paid for acquisitions of Sanna and TGC during the year. In the prior year, the Company had considerably more acquisitions which resulted in higher transaction costs which consisted primarily of non-cash transactions, and relate to fees and finders common shares issued pursuant to the acquisition of certain Organic Flower assets.
- Other general and operating costs increased to \$491,092 from \$Nil mostly from operating activities in Europe.
- Research and development costs decreased to \$394,945 from \$396,479 as the Company completed several acquisitions and continued to develop its products to be ready for sale. The costs are comparable to the prior period.
- The Company incurred decreased production costs of \$292,117 from \$Nil mostly related to its manufacturing facility in Winnipeg for edible productions during the year ended December 31, 2020.
- The Company incurred property taxes and fees of \$124,803 which are related to the properties owned by its subsidiaries during the year ended December 31, 2020.
- The Company recognized a fair value movement gain on convertible loan receivable of \$4,553,744 and is related to a new convertible loan entered into in late 2019.
- The Company recognized an impairment loss on its investments of \$8,459,815 as a result of revaluation during the year, \$417,598 relates to investments that have no future plans and \$8,042,217 relates to the impairment on the PSC loan.
- The Company recorded a provision on its loan receivable of \$212,033 (2019 - \$419,945) as a result of the Company being uncertain whether the loan amounts are collectable.
- The Company recorded an impairment loss on tangible and intangible assets of \$16,532,620 (2019 - \$4,089,089) related to the intangible assets acquired from its subsidiaries as a result of revaluation during the year. The Company recorded impairment loss on intangible assets acquired from The Good Company, Sanna Health Corp. and AAA Heidelberg Inc..
- The Company recorded an impairment loss on its goodwill of \$17,153,030 (2019 - \$5,724,369) related to the goodwill acquired from The Good Company and Canutra during the year as a result of revaluation.
- Loss on equity accounted investments increased to \$4,732,476 from \$2,217,148 as a result of equity accounted investments reporting higher losses.
- The Company recorded \$639,784 gain on debt settlement (2019: \$17,537) as a result of settling debts with certain creditors during the period ended December 31, 2020.
- The Company earned revenues of \$1,491,678 from \$3,888 from sale of consumer cannabis products where minimal sales had occurred in the prior year.
- The Company had \$308,672 gain on sale of assets (2019: loss on sale of assets of \$2,392,236), in the comparative period ended December 31, 2019, the Company sold.
- The Company recorded \$Nil gain on the sale of marketable securities (2019: \$1,178,210) as the Company sold all its investments in marketable securities to JJ Wolf in the prior year.
- The Company write-off prepaid expenses of \$553,668 (2019: \$Nil) as a result of certain investments becoming inactive during the period ended December 31, 2020.
- The Company wrote-off accounts receivable of \$1,158,462 (2019: \$446,610) primarily due to the CRA denying the Company of GST/HST claims.
- The Company wrote-off inventory of \$2,169 (2019: \$Nil) as a result of inventory obsolescence.
- The Company recorded a \$Nil loss on disposition of equity investments (2019: \$362,499) as the Company did not dispose of any equity investments in the current period. In the prior year, the Company recorded a realized loss on disposition of PSC for \$994,672 which was partially offset with a realized gain on sale of Glow Life to JJ Wolf for \$632,173, resulting in a net loss on sale of equity investments of \$362,499.
- The Company recorded interest income of \$101,671 (2019: \$32,745) as a result of interest earned on its loan receivables during the year.
- The Company recorded a gain on loan payable of \$32,540 (2019: \$Nil) related to a gain on the loan received from JJ Wolf.

AGRAFLORA ORGANICS INTERNATIONAL INC.
Management's Discussion and Analysis
(Expressed in Canadian Dollars)

RESULTS OF OPERATIONS (CONTINUED)

- The Company recorded government grant revenue of \$273,124 (2019: \$Nil) as a result of the Company receiving government CEBA loans during the year and recording the revenue earned during the period, and government grant revenues from the Government of Manitoba for its progression of its projects with the government.
- The Company wrote-off \$29,210,673 of its convertible loan receivable (2019: \$Nil) as a result of the revaluation of the loan receivable during the year.

Below is a break-down of the various consulting fees incurred by the Company:

	Year ended December 31,	
	2020	2019
	\$	\$
Management fees	3,323,086	4,633,587
Research and development consulting fees	226,600	1,239,092
Advisory and business development consulting fees	3,688,029	6,441,945
Marketing consulting fees	429,143	442,001
Security consulting fees	10,150	14,000
Distribution consulting fees	-	380,000
Legal consulting fees	-	37,534
Total	7,677,008	13,188,159

REVENUE AND COST OF SALES ANALYSIS

	Year ending December 31, 2020	
	2020	2019
	\$	\$
Sales	1,491,678	3,888
Cost of goods sold	(525,399)	(12,996)
Gross profit	525,939	(9,108)
Gross profit %	35%	(234%)

- In the prior year, the Company had minimal sales, therefore the prior period is not indicative of the Company's future performance.
- The Company sales include various hemp health products and cannabis to pharmacies, medical and recreational customers. The majority of the sales were earned in the Company's subsidiary, The Good Company GmbH.
- Cost of goods sold include all expenditures related to the products. This includes ingredients and manufacturing costs, as well as cost of purchasing the products.
- During the year ended December 31, 2020, revenues increased from \$3,888 to \$1,491,678. The Company has a gross profit of 35% which reflects the Company's growth and initiation of sales during the current fiscal year.

LIQUIDITY

Liquidity and Capital Resources

The financial statements have been prepared on a going-concern basis, which assumes the realization of assets and liquidation of liabilities in the normal course of business. Continuing operations, as intended, are dependent on management's ability to raise required funding through future equity issuances, its ability to execute the Company's business interests and develop profitable operations or a combination thereof, which is not assured, given today's volatile and uncertain financial markets. The Company may revise the Company's business programs depending on its working capital position.

AGRAFLOA ORGANICS INTERNATIONAL INC.
Management's Discussion and Analysis
(Expressed in Canadian Dollars)

LIQUIDITY (CONTINUED)

Liquidity and Capital Resources (Continued)

The Company has financed its operations to date through the issuance of common shares.

	December 31, 2020	December 31, 2019
	\$	\$
Working capital (deficit)	(24,519,416)	(3,892,638)
Total liabilities	58,004,320	41,517,146
Deficit	(207,377,315)	(123,209,175)

Other than the above-mentioned current liabilities, the Company has no short-term capital spending requirements and future plans and expectations are based on the assumption that the Company will realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation. There can be no assurance that the Company will be able to obtain adequate financing in the future or if available that such financing will be on acceptable terms. If adequate financing is not available when required, the Company may be required to delay, scale back or eliminate various programs and may be unable to continue in operation. The Company may seek such additional financing through debt or equity offerings. Any equity offering will result in dilution to the ownership interests of the Company's shareholders and may result in dilution to the value of such interests.

The Company's future revenues, if any, are expected to be from the sale of hemp and cannabis and their related derivatives. The economics of developing and producing cannabis are affected by many factors including the cost of operations, variations in the quality of cannabis, and the price of cannabis and related derivatives. There is no guarantee that the Company will be able to successfully develop its production facilities and distribution channels.

Liquidity and Capital Resources – Cash Flow

Operating Activities:

During the year ended December 31, 2020, \$4,689,888 (2019 - \$13,813,551) cash was used in operating activities. This consisted mainly of cash paid for consulting, corporate development, due diligence and day to day expenditures related to the various acquisitions completed during the period. Extensive due diligence was performed over the course of the year for the acquisitions completed and the Company notes the overall change in the market place. In the comparative period, the Company incurred a higher net loss due to overall higher operating activities, therefore it is reasonable that the cash used was higher comparatively.

Financing Activities:

During the year ended December 31, 2020, \$12,318,967 (2019 - \$38,376,853) of cash was provided by financing activities. The Company issued convertible loan for gross proceeds of \$9,770,000, issued common shares with proceeds of \$2,420,250 and repaid lease liability of \$510,303.

Investing Activities:

During the year ended December 31, 2020, \$11,430,984 (2019 - \$31,205,895) was used in investing activities. This primarily consists of payments made on investments made in PSC, and property plant and equipment of \$5,612,827 and receipt of a deferred revenue of \$322,000 for sale of investments subsequent to year-end. The Company is also working on funding the needs of the Company's subsidiaries.

LIQUIDITY (CONTINUED)

Liquidity and Capital Resources – Cash Flow (Continued)

Management's current strategy is to continue vertical integration through acquisition and partnership with different companies. The Organic Flower acquisition in Q2 and Q3 2019 and the Sanna and The Good Company acquisitions in 2020 has made the company truly vertically integrated and will allow the Company to achieve high margins on the sales of cannabis as well as expand the company's distribution capabilities. Edible prices generate extremely attractive margins and this market segment will allow the company to be very profitable. The edibles industry in the US and Canada is expected to double in the next 3 years and the Company through the Organic Flower acquisition now has assets in every part of the value chain. The Company will also issue shares to raise funds as necessary.

In the event that proceeds from any future financings are insufficient to cover planned expenditures, Management will allocate available resources in such manner as deemed to be in the Company's best interest. This may result in a significant reduction in the scope of existing and planned operations.

These financial statements do not reflect any adjustments related to the recoverability and classification of assets or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

OFF-BALANCE SHEET ARRANGEMENTS

The Company has no off-balance sheet arrangements that would potentially affect current or future operations or the financial condition of the Company.

PROPOSED TRANSACTIONS

The Company does not currently have any proposed transactions approved by the Board of Directors. All current transactions are fully disclosed in the consolidated financial statements for the year ended December 31, 2020.

INVESTOR RELATIONS

The Company has not entered into any investor relations contracts and all investor relation activity is carried out by directors and officers of the Company.

COMMITMENTS

During the year ended December 31, 2019, the Company entered into Supply Agreement with Vendure Genetics Labs Inc. ("Vendure") to purchase from Vendure certain plants, plant matter, related plant-based products and Vendure's right, title and interest, including the intellectual property rights in the products for a purchase price of \$200,000 (paid) and 281,690 common shares (issued with a fair value of \$146,478). Under the agreement, the Company is committed to issue a further \$200,000 worth of common shares at the time of awarding Cannabis Cultivation license, and a further number of shares equal to \$150,000 per year on each of March 31, 2020, March 31, 2021, March 31, 2022, and March 31, 2023. During the year ended December 31, 2020, the Company terminated the agreement with Vendure and settled \$220,000 of debt with the issuance of 4,000,000 common shares and recorded a gain on debt settlement of \$10,000.

AGRAFLORA ORGANICS INTERNATIONAL INC.
Management's Discussion and Analysis
(Expressed in Canadian Dollars)

COMMITMENTS (CONTINUED)

During the year ended December 31, 2019, the Company entered into a Lease Agreement for a leased facility in Manitoba. The lease expires on May 31, 2029 and has the following estimated annual payments:

2021 – May 2024	\$309,510 per annum
June 2024 – May 2029	\$340,461 per annum

During the year ended December 31, 2020, the Company acquired from Sanna a right-of-use asset for a leased manufacturing facility in Ontario. The lease expires on December 31, 2029 with option to extend the lease term of two additional terms of five years each and has the following estimated annual payments:

January 2021 – December 2022	\$225,000 per annum
January 2023 – December 2024	\$240,000 per annum
January 2025 – December 2026	\$255,000 per annum
January 2027 – December 2029	\$270,000 per annum

Legal Claims

The Company has legal claims related to Sanna Health Corp.'s past termination of its former President and CEO who was terminated before Sanna was acquired by the Company for cause due to dereliction of duties. The former President and CEO is claiming accrued and unpaid amounts of \$137,976, total damages of \$1,300,000, and entitlement of 6,000,000 restricted share units and 6,800,000 fully-vested shares (with strike price of \$0.16) in Sanna Health Corp., and punitive damages of \$250,000. The Company believes these claims are without merit and will vigorously defend itself.

CONTINGENT LIABILITY

On May 18, 2011, the Company received an order granted by a court in Lima, Peru indicating that the Company is responsible for a debt of US\$209,403 incurred by a former subsidiary of the Company. The Company did not receive notice of the Peruvian legal proceedings and is seeking advice concerning an application to set aside the order. The Company retained Peruvian legal counsel who advised that the Company is not responsible for this obligation.

The most recent contact from Peru indicates that the order has been dropped but the Company has not received formal notice of such release. No amounts have been recorded in the Company's books and records regarding this issue.

AGRAFLORA ORGANICS INTERNATIONAL INC.
Management's Discussion and Analysis
(Expressed in Canadian Dollars)

RELATED PARTY TRANSACTIONS

The Directors and Executive Officers of the Company as of the date of this report are as follows:

Elise Coppen	CEO, Director
Brandon Boddy	Former CEO and Chairman and Corporate Secretary
Peter Nguyen	CFO
Brian O'Neill	Director
Jerry Habuda	Director
Joseph Perino	Director
Christopher Hornung	Former Director

The Company has identified the directors and senior officers as key management personnel. The following table lists the compensation costs paid directly or to companies controlled by key management personnel for the years ended December 31, 2020 and 2019:

Year ended December 31, 2020		
	Consulting and Management Fees	Share-based Compensation
	\$	\$
Legal fees paid/accrued to a private company controlled by a director	7,950	56,433
Consulting fees paid to current directors	-	112,866
Consulting fees paid/accrued to a former director	58,850	-
Consulting fees paid/accrued to a company controlled by the former Corporate Secretary	34,978	-
Consulting fees paid/accrued to a private company controlled by the CFO	102,000	-
Consulting fees paid/accrued to a private company controlled by the CEO	240,000	135,440
	443,778	304,739

Year ended December 31, 2019		
	Consulting and Management Fees	Share-based compensation
	\$	\$
Consulting fees paid/accrued to a company controlled by the former CFO	57,171	70,350
Consulting fees paid/accrued to a private company controlled by the former CEO	3,595,483	-
Consulting fees paid/accrued to a director	120,000	160,976
Consulting fees paid/accrued to a private company controlled by a director	29,541	156,441
Directors	-	203,514
Former Corporate Secretary	103,538	65,851
Consulting fees paid/accrued to a private company controlled by the CFO	45,000	-
Consulting fees paid/accrued to a private company controlled by the CEO	590,000	995,616
	4,540,733	1,652,748

AGRAFLORA ORGANICS INTERNATIONAL INC.
Management's Discussion and Analysis
(Expressed in Canadian Dollars)

RELATED PARTY TRANSACTIONS (CONTINUED)

Amounts due to and due from related parties are unsecured, non-interest bearing and due on demand. At December 31, 2020, \$165,778 (December 31, 2019 - \$123,341) is owing to related parties for unpaid fees which are included in accounts payable and accrued liabilities.

CONFLICTS OF INTEREST

The Company's directors and officers may serve as directors or officers, or may be associated with other reporting companies, or have significant shareholdings in other public companies. To the extent that such other companies may participate in business or asset acquisitions, dispositions, or ventures in which the Company may participate, the directors and officers of the Company may have a conflict of interest in negotiating and concluding on terms with respect to the transaction. If a conflict of interest arises, the Company will follow the provisions of the Business Corporations Act (BC) ("Corporations Act") dealing with conflict of interest. These provisions state that where a director has such a conflict, that director must, at a meeting of the Company's directors, disclose his or her interest and refrain from voting on the matter unless otherwise permitted by the Corporations Act. In accordance with the laws of the Province of British Columbia, the directors and officers of the Company are required to act honestly, in good faith, and in the best interest of the Company.

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Fair value of financial instruments

The carrying values of cash, amounts receivable, advances to related parties, loans receivable, accounts payable and accrued liabilities, and advances from related parties approximate their carrying values due to the immediate or short-term nature of these instruments.

IFRS 13, *Fair Value Measurement*, establishes a fair value hierarchy that prioritizes the input to valuation techniques used to measure fair value as follows:

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company's cash, marketable securities and accounts payable and accrued liabilities are measured using level 1 inputs.

The following is an analysis of the Company's financial assets measured at fair value as at and December 31, 2020 and 2019:

	As at December 31, 2020		
	Level 1	Level 2	Level 3
Cash	\$ 274,390	-	-
Derivative liabilities	-	-	\$ 10,138,800
Contingent consideration	-	-	\$ 5,000,000
	As at December 31, 2019		
	Level 1	Level 2	Level 3
Cash	\$ 4,076,295	-	-
Convertible debenture receivable	-	\$ 24,636,507	-
Derivative liability	-	-	\$ 1,465,129
Investments	-	-	\$ 88,022

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONTINUED)

Financial risk management

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. Financial instruments that potentially subject the Company to credit risk consist primarily of cash, convertible debentures receivable and loans receivable. The Company limits its exposure to credit risk by placing its cash with a high credit quality financial institution in Canada.

The loans receivable and convertible debentures receivable expose the Company to credit risk and the Company has limited this exposure by securing one of the loans with collateral; the other loan is unsecured. The convertible debentures receivable is convertible into shares of the entity.

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in raising funds to meet commitments associated with financial instruments and with the construction of its cannabis facilities in Ontario and British Columbia. The Company manages liquidity risk by maintaining adequate cash balances.

The Company's expected source of cash flow in the upcoming year will be through equity financing. Cash on hand at December 31, 2020 and expected cash flows for the next 12 months are sufficient to fund the Company's ongoing operational needs. The Company will need additional funding through equity or debt financing, or a combination thereof, to complete its facilities.

Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, foreign exchange rates, and commodity and equity prices.

Interest rate risk

Interest rate risk consists of two components: to the extent that payments made or received on the Company's monetary assets and liabilities are affected by changes in the prevailing market interest rates. The Company is exposed to interest rate cash flow risk; and to the extent that changes in prevailing market rates differ from the interest rate in the Company's monetary assets and liabilities, the Company is not exposed to interest rate risk as its agreements are all done with fixed interest rates.

Current financial assets and current financial liabilities are generally not exposed to interest rate risk because of their short-term nature and maturity.

Foreign currency risk

Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is exposed to foreign currency risk to the extent that monetary assets and liabilities are denominated in foreign currency. One of the Company's subsidiary's business is conducted in Euro. As such, the Company is exposed to foreign currency risk in fluctuations among the Canadian dollar, the Euro. Fluctuations in the exchange rate among the Canadian dollar and the Euro may have an adverse effect on the Company's business and financial condition. Fluctuations do not have a significant impact on operating results.

The Company has not entered into any foreign currency contracts to mitigate foreign currency risk.

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONTINUED)

Capital risk management

The Company manages its capital to ensure that it will be able to continue as a going concern while maximizing the return to stakeholders through a suitable debt and equity balance appropriate for an entity of the Company's size and status. The Company's overall strategy remains unchanged from last year.

The capital structure of the Company consists of equity attributable to common shareholders. The availability of new capital will depend on many factors including positive stock market conditions, and the experience of management. The Company is not subject to any external covenants on its capital.

ADDITIONAL SHARE INFORMATION

As at the date of this MD&A, the Company had 1,939,506,778 common shares outstanding, 370,001,292 warrants outstanding with exercise prices ranging from \$0.05 to \$0.50 and expiring at various dates to July 8, 2025 and 122,490,000 stock options outstanding with exercise prices ranging from \$0.075 to \$0.460 and expiring at various dates to April 30, 2025.

NEW SIGNIFICANT ACCOUNTING POLICIES

Amendments to IFRS 3, Business Combinations ("IFRS 3")

In October 2018, the IASB issued "Definition of a Business (Amendments to IFRS 3)". The amendments clarify the definition of a business, with the objective of assisting entities to determine whether a transaction should be accounted for as a business combination or as an asset acquisition. The amendment provides an assessment framework to determine when a series of integrated activities is not a business.

The amendments are effective for business combinations and asset acquisitions occurring on or after January 1, 2020.

There are no other pending IFRSs or IFRIC interpretations that are expected to be relevant to the Company's financial statements.

Amendments to IAS 1: Classification of Liabilities as Current or Non-current

The amendment clarifies the requirements relating to determining if a liability should be presented as current or non-current in the statement of financial position. Under the new requirement, the assessment of whether a liability is presented as current or non-current is based on the contractual arrangements in place as at the reporting date and does not impact the amount or timing of recognition. The amendment applies retrospectively for annual reporting periods beginning on or after January 1, 2022. The Company is currently evaluating the potential impact of these amendments on the Company's consolidated financial statements.

OTHER RISKS AND UNCERTAINTIES

In conducting its business, the Company is subject to a number of other risks and uncertainties that could have a material adverse effect on the Company's business prospects or financial condition that could result in a delay or indefinite postponement in the development of the Company's interests.

Going concern

The Company's financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The continuing operations of the Company are dependent upon its ability to obtain the necessary financing to meet its on-going commitments.

OTHER RISKS AND UNCERTAINTIES (CONTINUED)

Risks Related to the Company's Business

This section discusses factors relating to the business of Company that should be considered by both existing and potential investors. The information in this section is intended to serve as an overview and should not be considered comprehensive and the Company may face risks and uncertainties not discussed in this section, or not currently known to us, or that we deem to be immaterial. All risks to the Company's business have the potential to influence its operations in a materially adverse manner.

Reliance on Licensing

The ability of the Company to continue its business of growth, storage and distribution of medical marijuana is dependent on the good standing of all licenses, including the licenses to produce and sell cannabis and hemp derivatives, and adherence to all regulatory requirements related to such activities. Any failure to comply with the terms of the licenses, or to renew the licenses after their expiry dates, would have a material adverse impact on the financial condition and operations of the business of the Company.

Although the Company believes that it will meet the requirements of future extensions or renewals of the licenses, there can be no assurance that the regulating bodies will extend or renew the licenses, or if extended or renewed, that they will be extended or renewed on the same or similar terms. Should the regulatory bodies not extend or renew the licenses, or should they renew the licenses on different terms, the business, financial condition and operating results of the Company would be materially adversely affected.

Change in Law, Regulations and Guidelines

The Company's business is subject to a variety of laws, regulations and guidelines relating to marketing, distribution, cultivation, management and sale and disposal of medical marijuana but also laws and regulations relating to health and safety, the conduct of operations and the protection of the environment. Changes to such laws, regulations and guidelines may cause adverse effects to the Company's operations. The Liberal Party of Canada, which has formed the current federal Government of Canada, has made electoral commitments to legalize, regulate and tax recreational cannabis use in Canada. On April 13, 2017, the Government of Canada introduced the Cannabis Act. On June 19, 2018, Prime Minister Justin Trudeau announced that the Cannabis Act and its regulations will come into force in Canada on October 17, 2018, in order to provide the provinces and territories time to prepare for retail sales. The Cannabis Act passed its final legislative step and received Royal Assent on June 21, 2018. The legislative framework pertaining to the Canadian recreational cannabis market will be subject to significant provincial and territorial regulation.

Regulatory Risk

Achievement of the Company's business objectives are contingent, in part, upon compliance with the regulatory requirements, enacted by these government authorities and obtaining all regulatory approvals, where necessary, for the sale of its products. The Company cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by government authorities. Any delays in obtaining, or failure to obtain regulatory approvals would significantly delay the development of markets and products and could have a material adverse effect on the Company's business, results of operation and financial condition.

Realization of Growth Targets

The Company's ability to produce marijuana is affected by a number of factors, including plant design errors, non-performance by third party contractors, increases in materials or labour costs, construction performance falling below expected levels of output or efficiency, environmental pollution, contractor or operator errors, breakdowns, aging or failure of equipment or processes, labour disputes, as well as factors specifically related to indoor agricultural practices, such as reliance on provision of energy and utilities to the facility, and potential impacts of major incidents or catastrophic events on the facility, such as fires, explosions, earthquakes or storms.

OTHER RISKS AND UNCERTAINTIES (CONTINUED)

Limited Operating History and No Assurance of Profitability

The Company is subject to all of the business risks and uncertainties associated with any early stage enterprise, including under-capitalization, cash shortages, limitation with respect to personnel, financial and other resources, and lack of revenues. The Company has incurred operating losses in recent periods. The Company may not be able to achieve or maintain profitability and may continue to incur significant losses in the future.

In addition, the Company expects to continue to increase operating expenses as it implements initiatives to grow its business. If the Company's revenues do not increase to offset these expected increases in costs and operating expenses, the Company will not be profitable. There is no assurance that the Company will be successful in achieving a return on shareholders' investments and the likelihood of success must be considered in light of the early stage of operations.

Unfavorable Publicity or Consumer Perception

The success of the medical marijuana industry may be significantly influenced by the public's perception of marijuana's medicinal applications. Medical marijuana is a controversial topic, and there is no guarantee that future scientific research, publicity, regulations, medical opinion and public opinion relating to medical marijuana will be favorable. The medical marijuana industry is an early-stage business that is constantly evolving with no guarantee of viability. The market for medical marijuana is uncertain, and any adverse or negative publicity, scientific research, limiting regulations, medical opinion and public opinion relating to the consumption of medical marijuana may have a material adverse effect on our operational results, consumer base and financial results.

Additional Financing

There is no guarantee that the Company will be able to execute on its strategy. The continued development of the Company may require additional financing. The failure to raise such capital could result in the delay or indefinite postponement of current business strategy or the Company ceasing to carry on business. There can be no assurance that additional capital or other types of financing will be available if needed or that, if available, the terms of such financing will be favorable to the Company. If additional funds are raised through issuances of equity or convertible debt securities, existing shareholders could suffer significant dilution. In addition, from time to time, the Company may enter into transactions to acquire assets or the shares of other Companies. These transactions may be financed wholly or partially with debt, which may temporarily increase the Company's debt levels above industry standards. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for the obtain additional capital and to pursue business opportunities, including potential acquisitions. Debt financings may contain provisions, which, if breached, may entitle lenders to accelerate repayment of loans and there is no assurance that the Company would be able to repay such loans in such an event or prevent the enforcement of security granted pursuant to such debt financing. The Company may require additional financing to fund its operations to the point where it is generating positive cash flows. Negative cash flow may restrict the Company's ability to pursue its business objectives.

Uninsured or Uninsurable Risk

The Company may be subject to liability for risks against which it cannot insure or against which the Company may elect not to insure due to the high cost of insurance premiums or other factors. The payment of any such liabilities would reduce the funds available for the Company's normal business activities. Payment of liabilities for which the Company does not carry insurance may have a material adverse effect on the Company's financial position and operations.

Key Personnel

The Company's success will depend on its directors' and officers' ability to develop and execute on the Company's business strategies and manage its ongoing operations, and on the Company's ability to attract and retain key quality assurance, scientific, sales, public relations and marketing staff or consultants now that production and selling operations have begun. The loss of any key personnel or the inability to find and retain new key persons could have a material adverse effect on the Company's business. Competition for qualified technical, sales and marketing staff, as well as officers and directors can be intense, and no assurance can be provided that the Company will be able to attract or retain key personnel in the future, which may adversely impact the Company's operations.

OTHER RISKS AND UNCERTAINTIES (CONTINUED)

Strategic Alliances

The Company currently has, and may in the future enter into, strategic alliances with third parties that the Company believes will complement or augment its existing business. The Company's ability to complete strategic alliances is dependent upon, and may be limited by, the availability of suitable candidates and capital. In addition, strategic alliances could present unforeseen integration obstacles or costs, may not enhance our business, and may involve risks that could adversely affect the Company, including significant amounts of management time that may be diverted from operations in order to pursue and complete such transactions or maintain such strategic alliances. Future strategic alliances could result in the incurrence of additional debt, costs and contingent liabilities, and there can be no assurance that future strategic alliances will achieve, or that the Company's existing strategic alliances will continue to achieve, the expected benefits to the Company's business or that the Company will be able to consummate future strategic alliances on satisfactory terms, or at all. Any of the foregoing could have a material adverse effect on the Company's business, financial condition and results of operations.

New Product Development

The medical cannabis industry is, and the recreational cannabis industry will be, in its early stages of development and it is likely that the Company, and its competitors, will seek to introduce new products in the future. In attempting to keep pace with any new market developments, the Company may need to expend significant amounts of capital in order to successfully develop and generate revenues from new products introduced by the Company. As well, the Company may be required to obtain additional regulatory approvals from Health Canada and any other applicable regulatory authority, which may take significant amounts of time. The Company may not be successful in developing effective and safe new products, bringing such products to market in time to be effectively commercialized, or obtaining any required regulatory approvals, which, together with any capital expenditures made in the course of such product development and regulatory approval processes, may have a material adverse effect on the Company's business, financial condition and results of operations.

Litigation

The Company may become party to litigation, mediation and/or arbitration from time to time in the ordinary course of business which could adversely affect its business. Monitoring and defending against legal actions, whether or not meritorious, can be time-consuming, divert management's attention and resources and cause the Company to incur significant expenses. In addition, legal fees and costs incurred in connection with such activities may be significant and we could, in the future, be subject to judgments or enter into settlements of claims for significant monetary damages. While the Company has insurance that may cover the costs and awards of certain types of litigation, the amount of insurance may not be sufficient to cover any costs or awards. Substantial litigation costs or an adverse result in any litigation may adversely impact the Company's business, operating results or financial condition.

Agricultural Operations

Since the Company's business will revolve mainly around the growth of medical marijuana, an agricultural product, the risks inherent with agricultural businesses will apply. Such risks may include disease and insect pests, among others. Although the Company expects to grow its product in a climate controlled, monitored, indoor location, there is no guarantee that changes in outside weather and climate will not adversely affect production. Further, any rise in energy costs may have a material adverse effect on the Company's ability to produce medical marijuana.

Transportation Disruptions

The Company will depend on fast, cost-effective and efficient courier services to distribute its product. Any prolonged disruption of this courier service could have an adverse effect on the financial condition and results of operations of the Company. Rising costs associated with the courier service used by the Company to ship its products may also adversely impact the business of the Company and its ability to operate profitably.

OTHER RISKS AND UNCERTAINTIES (CONTINUED)

Fluctuating Prices of Raw Materials

The Company's revenues will be derived from the production, sale and distribution of marijuana. The price of production, sale and distribution of marijuana will fluctuate widely due to how young the marijuana industry is and is affected by numerous factors beyond the Company's control including international, economic and political trends, expectations of inflation, currency exchange fluctuations, interest rates, global or regional consumptive patterns, speculative activities and increased production due to new production and distribution developments and improved production and distribution methods. The effect of these factors on the price of product produced by the Company and, therefore, the economic viability of any of the Company's business, cannot accurately be predicted.

Political and Economic Instability

The Company may be affected by possible political or economic instability. The risks include, but are not limited to, terrorism, military repression, extreme fluctuations in currency exchange rates and high rates of inflation. Changes in medicine and agriculture development or investment policies or shifts in political attitude in certain countries may adversely affect the Company's business. Operations may be affected in varying degrees by government regulations with respect to restrictions on production, distribution, price controls, export controls, income taxes, expropriation of property, maintenance of assets, environmental legislation, land use, land claims of local people and water use. The effect of these factors cannot be accurately predicted.

Growth Expansion Efforts

There is no guarantee that the Company's intentions to acquire and/or construct additional cannabis production and manufacturing facilities in Canada and in other jurisdictions with federal legal cannabis markets, and to expand the Company's marketing and sales initiatives will be successful. Any such activities will require, among other things, various regulatory approvals, licenses and permits and there is no guarantee that all required approvals, licenses and permits will be obtained in a timely fashion or at all. There is also no guarantee that the Company will be able to complete any of the foregoing activities as anticipated or at all. The failure of the Company to successfully execute its expansion strategy (including receiving required regulatory approvals and permits) could adversely affect the Company's business, financial condition and results of operations and may result in the Company failing to meet anticipated or future demand for its cannabis-based pharmaceutical products, when and if it arises. Moreover, actual costs for construction may exceed the Company's budgets. As a result of construction delays, cost overruns, changes in market circumstances or other factors, the Company may not be able to achieve the intended economic benefits from the construction of the new facilities, which in turn may materially and adversely affect its business, prospects, financial condition and results of operations.

Execution of Future Acquisitions or Dispositions

Material acquisitions, dispositions and other strategic transactions involve a number of risks, including: (i) potential disruption of the Company's ongoing business; (ii) distraction of management; (iii) the Company may become more financially leveraged; (iv) the anticipated benefits and cost savings of those transactions may not be realized fully or at all or may take longer to realize than expected; (v) increasing the scope and complexity of the Company's operations, and (vi) loss or reduction of control over certain of the Company's assets. The presence of one or more material liabilities of an acquired company that are unknown to the Company at the time of acquisition could have a material adverse effect on the results of operations, business prospects and financial condition of the Company. A strategic transaction may result in a significant change in the nature of the Company's business, operations and strategy. In addition, the Company may encounter unforeseen obstacles or costs in implementing a strategic transaction or integrating any acquired business into the Company's operations.

OTHER RISKS AND UNCERTAINTIES (CONTINUED)

Market Risk for Securities

The market price for the Common Shares of the Company could be subject to wide fluctuations. Factors such as commodity prices, government regulation, interest rates, share price movements of peer companies and competitors, as well as overall market movements, may have a significant impact on the market price of the Company. The stock market has from time to time experienced extreme price and volume fluctuations, which have often been unrelated to the operating performance of particular companies.

Competition

There is potential that the Company will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and manufacturing and marketing experience than the Company. Increased competition by larger and better financed competitors could materially and adversely affect the business, financial condition and results of operations of the Company.

Because of the early stage of the industry in which the Company intends to operate, the Company expects to face additional competition from new entrants. If the number of users of medical marijuana in Canada increases, the demand for products will increase and the Company expects that competition will become more intense, as current and future competitors begin to offer an increasing number of diversified products. To be competitive, the Company will require a continued high level of investment in research and development, marketing, sales and client support. The Company may not have sufficient resources to maintain research and development, marketing, sales and client support efforts on a competitive basis which could materially affect the business, financial condition and results of operations of the Company.

Global Economy

An economic downturn of global capital markets has been shown to make the raising of capital by equity or debt financing more difficult. The Company will be dependent upon the capital markets to raise additional financing in the future, while it establishes a user base for its products. As such, the Company is subject to liquidity risks in meeting its development and future operating cost requirements in instances where cash positions are unable to be maintained or appropriate financing is unavailable. These factors may impact the Company's ability to raise equity or obtain loans and other credit facilities in the future and on terms favorable to the Company and its management. If uncertain market conditions persist, the Company's ability to raise capital could be jeopardized, which could have an adverse impact on the Company's operations and the trading price of the Company's shares on the Exchange.

ADDITIONAL INFORMATION

Additional information relating to the Company can be found on the SEDAR at www.sedar.com.